China’s medical device industry is entering a new phase of globalization in which international expansion is no longer optional but a strategic imperative for sustained growth. As domestic pricing pressure intensifies and policy reforms reshape the competitive landscape, leading companies are accelerating the shift from volume-driven growth to innovation-led, globally diversified models. Developed in collaboration with the Singapore Economic Development Board, this report draws on frontline perspectives from Chinese medtech companies operating in Singapore and across Southeast Asia.
Against this backdrop, Southeast Asia is emerging as a natural first location for international expansion. The region offers a compelling combination of strong demand growth, improving healthcare infrastructure and relatively accessible regulatory pathways, which creates a pragmatic entry point for companies building global capabilities.
Within Southeast Asia, Singapore stands out as a critical anchor for regional and global strategy. Its integrated ecosystem — spanning regulatory efficiency, advanced manufacturing, R&D capabilities and strong international connectivity — enables companies to centralize regional operations, streamline market entry and scale more effectively across multiple markets.
At the company level, the path to globalization is increasingly differentiated. Leading medtech players are adopting a range of operating models, from distributor-led approaches to fully localized platforms, depending on product complexity, service requirements and long-term strategic ambition. The ability to align operating model choices with capability development is emerging as a key determinant of success.
This report provides a practical lens for executives navigating this transition, with clear implications for how to prioritize markets, design operating models and allocate resources in building a sustainable global footprint.
Complete the form below to download the full PDF and gain deeper insights into the key opportunities and practical pathways for Chinese medtech companies expanding in Southeast Asia and globally.
